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Abstract: Dravet syndrome is a severe rare epileptic disease caused by mutations in the SCN1A 
gene coding for the Nav1.1 protein, a voltage-gated sodium channel alpha subunit. We have made 
a knock-out of the paralytic gene, the single Drosophila melanogaster gene encoding this type of pro-
tein, by homologous recombination. These flies showed a heat-induced seizing phenotype, and 
sudden death in long term seizures. In addition to seizures, neuromuscular alterations were ob-
served in climbing, flight, and walking tests. Moreover, they also manifested some cognitive alter-
ations, such as anxiety and problems in learning. Electrophysiological analyses from larval motor 
neurons showed a decrease in cell capacitance and membrane excitability, while persistent sodium 
current increased. To detect alterations in metabolism, we performed an NMR metabolomic pro-
filing of heads, which revealed higher levels in some amino acids, succinate, and lactate; and also 
an increase in the abundance of GABA, which is the main neurotransmitter implicated in Dravet 
syndrome. All these changes in the paralytic knock-out flies indicate that this is a good model for 
epilepsy and specifically for Dravet syndrome. This model could be a new tool to understand the 
pathophysiology of the disease and to find biomarkers, genetic modifiers and new treatments. 




1.1. Dravet Syndrome 
Dravet syndrome (DS, ORPHA:33069), or epileptic encephalopathy with early onset 
6 (EIEE6), or severe childhood myoclonic epilepsy (SMEI), is a childhood epilepsy [1–3]. 
DS has an early onset in the first few months of life, usually triggered by fever, with a 
hemiclonic or clonic seizure, affecting one or both sides of the body, respectively, which 
is followed by further episodes that can be prolonged and even result in status epilepticus 
(SE, duration over 5 min or repeated short episodes). With time, patients usually suffer 
more febrile or afebrile seizures that can be of different types from the initial ones: ton-
ic-clonic, myoclonic, absence. In addition to seizures, they can also suffer cognitive delay, 
movement disorders and, more seriously, sudden death in a relatively high proportion 
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(>10%). DS is a disease with a very low prevalence, it is estimated that one infant suffers it 
for every 20,000 to 40,000 births. In 80% of cases, this pathology is caused by the mutation 
in one of the SCN1A gene alleles [4]. The SCN1A gene codes for the Nav1.1 protein, 
which is the α subunit of the type I voltage-gated sodium channel. In 95% of cases the 
pathological mutations in SCN1A are de novo, there are no family members with the 
same mutation. It is assumed that the disease is caused by haploinsufficiency, that is, the 
expression of half of the protein encoded by SCN1A is not sufficient for the proper func-
tioning of neurons that express the channel. When the genetic basis of DS was uncovered 
[5], it came as a surprise since voltage-gated sodium channels are usually involved in the 
excitation of neuronal and muscular cells. The conundrum was resolved when it was 
found that the mutations primarily prevented the activation of GABAergic inhibitory 
interneurons, and not so much excitatory neurons, thus disrupting the excita-
tion/inhibition balance [6,7]. 
In DS and similar epileptic syndromes, seizures result in damage of neural tissue 
through oxidative stress, inflammation, and/or metabolic imbalance [8,9]. NMR metab-
olomics of serum samples of paediatric drug-resistant epilepsy patients revealed altera-
tions in metabolites related to inflammation and oxidative stress, such as increased 
N-acetyl-glycoproteins, lactate, creatine, glycine and lipids or decreased citrate [10]. 
These metabolites could be used as biomarkers to study disease progression, or to eval-
uate the effect of pharmacological interventions. 
The first-line treatment for epilepsy is anti-seizure drugs (ASDs). However, in spite 
of the availability of many ASDs, approximately one-third of patients fail to achieve 
seizure control or soon become resistant to the effects of the ASDs [11]. In DS, there are no 
efficient medications to control seizures and the neurological damage, although some 
first line ASDs, such as valproate, stiripentol, or benzodiacepines have shown limited 
effectiveness [12]. The most recent therapeutic development has been the successful 
clinical trials of cannabidiol [13], which was approved to treat DS in America and Europe 
in 2019. 
Although the majority of DS patients have mutations in the SCN1A gene, and these 
are always dominant, each mutation produces a different clinical picture and responds 
differently to anticonvulsant treatments [14]. Further proof of the complexity of the gen-
otype-phenotype correlation of SCN1A mutations is that, in addition to DS, these muta-
tions can cause a spectrum of epileptic neuropathy disorders. Given this picture, it is 
impossible to develop a single disease model that can be used to understand the disease 
mechanisms and to find new therapies for all the mutations known. The most effective 
approach to this would be the development of precision medicine models reproducing 
the genotypes of a wide range of mutations in SCN1A. At this time there are no curative 
treatments for DS, only palliative ones. 
1.2. The Paralytic Gene of Drosophila 
In rare diseases such as DS, with a low prevalence and a lack of therapeutic options, 
the International Rare Diseases Research Consortium (IRDiRC) guidelines recommend 
the use of non-mammalian disease models for a more efficient research [15]. Drosophila 
melanogaster has a gene, paralytic (para), which is equivalent to all the human genes en-
coding voltage-gated sodium channels (Nav1.X). In fact, mutations in para were known 
to cause seizures a decade before the discovery of the molecular basis of DS [16]. Muta-
tions in this gene are associated with epileptic episodes similar to those that occur in pa-
tients [17]. Flies mutant for the parabss1 allele, a bang-sensitive mutation, display a behav-
iour very similar to wild type flies under normal conditions, and alterations are only 
observed when exposed to a mechanical shock by vortexing for a few seconds. Crises 
show six different phases in adult flies and have an average duration of 240 s. (1) The in-
itial crisis lasts several seconds and manifests with shaking of the legs, abdominal con-
tractions, flutter and extension of the proboscis. (2) In the early state of paralysis: flies are 
immobile and without response to external stimuli. (3) The period of tonic-clonic crisis, 
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the fly remains motionless most of the time (tonic phase) but intermittently suffers from 
generalised shaking (clonic phase). (4) The recovery crisis, at this stage, the fly again 
presents movements similar to the initial crisis mixed with clonic activity. (5) In the re-
fractory period flies begin to behave normally but further crises cannot be induced by 
any external stimulus, unless stimulus strength is greatly increased. (6) After recovery the 
fly has exceeded the refractory state and by this time they can be stimulated again to 
present crises. Seizures can be triggered by different stimuli: mechanical (agitation), 
thermal, visual, or electrical. 
The Para protein sequence is considerably conserved, such that a majority of clinical 
mutations due to non-synonymous changes fall back on amino acids that are identical or 
similar. Because of these similarities, Drosophila has been used in studies to understand 
the mechanism of disease mutations in SCN1A [18]. As a result of its remarkable features 
as a model organism, Drosophila has also been used to find genetic and pharmacological 
modifiers of the para seizure phenotype, which can be directly relevant for DS [19]. 
Our overarching objective is to replace the Drosophila para gene with the human 
SCN1A gene harbouring mutations representing the clinical spectrum. For this, we are 
using a technique that has been specifically developed for gene replacement in Drosophila 
[20]. The first step in this strategy is the knock-out of the para gene by inserting a con-
struct that interrupts the expression of the gene, and also has a phiC31 phage attP site that 
can be used to insert human cDNAs. This initial step is interesting on its own since, if 
successful, it is expected to generate a null allele of the para gene due to the absence of a 
functional transcript, which in itself is a useful tool to understand the convulsive phe-
notype, but also can help us in the search for new treatments for DS. 
2. Materials and Methods 
2.1. Molecular Biology 
To generate the gene-targeting construct, two arms homology were designed. They 
flank the start codon in the first coding exon and successful recombination would gen-
erate a small deletion of 12 bp. The sequences of the primers that we used to generate the 
homology arms, and all the subsequent molecular biology analyses, are indicated in Ta-
ble A1. After high fidelity PCR with Pfu DNA polymerase (Biotools; Madrid, Spain) us-
ing genomic DNA of the wildtype Canton-S strain as a template, the fragments were di-
gested with the appropriate restriction enzymes (Thermo-Fisher Scientific; Waltham, 
Massachusetts) and cloned in the corresponding multiple cloning site of the pTV[Cherry] 
plasmid [20]. The resulting plasmid sequence was tested by Sanger sequencing. 
For quantitative PCR, total RNA was extracted from pools of 15–20 fly heads or 
whole larvae with Trizol (Thermo-Fisher Scientific; Waltham, Massachusetts). To gener-
ate the cDNA we used the qScript cDNA SuperMix kit (Quantabio; Beverly, Massachu-
setts). The quantitative PCR was performed with SYBR Green Master Mix (Applied Bio-
systems; Foster City, California) using a LightCycler 480 (Roche; Bassel, Switzerland). All 
the samples were analysed in triplicate and transcript levels were calculated by the 2−ΔΔCt 
method, with normalisation by comparing to expression of the rp49 reference gene. 
2.2. Generation of the paraKO Allele 
We used a homology-directed recombination technique developed by Baena-López 
et al., which comprises two steps [20]. First, we obtained a stock containing de donor 
construct inserted in the genome by P element transposase, since the donor plasmid is 
flanked by the P element inverted repeats. The transgenics were generated by the Dro-
sophila transgenics service at Centro de Biología Molecular Severo Ochoa in Madrid, and 
were selected by the red eye colour due to the mini-white reporter within the construct. 
Since we were going to target the first chromosome, we chose an insertion in the third 
chromosome to facilitate the process. We crossed individuals carrying the donor con-
struct to hs-FLP, hs-SceI flies and activated the heat shock promoter by incubation for 1 h 
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at 37 °C twice, during the second and third larval instars, to induce the excision and the 
linearisation of the construct. In the progeny, we selected females that had mosaic eyes, 
and crossed them to Ubi-Gal4 males, so that Gal4-directed expression of reaper, which is 
outside the arms of homology, would kill the cells where the construct had not excised or 
had re-inserted non-specifically. After scoring 15,000 flies, we selected 3 candidates by 
the presence of the eye colour marker, and one of them mapped to the first chromosome. 
The correct insertion was validated by PCR using different primer pairs (Table A1). We 
also generated a stock from a white-eyed sibling to be used as a control, since it would 
have the same genetic background as the paraKO, except for the gene editing of the para 
gene. To remove most of the insert, leaving only a minimal insertion with an attP site, 
paraKO/FM7c females were crossed to hs-Cre males and the progeny was heat shocked 
twice in second and third instar stages. Excision candidates were selected by the white 
eye colour, and validated by PCR with flanking primers and sequencing of the PCR 
product. 
2.3. Drosophila Husbandry and Genetics 
All the strains used in this work and their origin are listed in Table A2. The flies were 
cultured at 25 °C in standard cornmeal medium. Since the paraKO allele is homozy-
gous/hemizygous lethal, it was kept over an FM7c balancer chromosome. 
To determine the stage of lethality, and to select homozygous embryos before they 
died for RNA extraction, we used the FM7c-GFP balancer chromosome. Parental flies 
were allowed to mate in a standard vial and then transferred to egg-laying plates con-
taining 25% apple juice and 2.5% agar supplemented with fresh yeast paste. Adults were 
transferred to a fresh plate after 6 h, and embryos were allowed to age for a further 12 h, 
and selected according to the presence or absence of GFP fluorescence. For RNA extrac-
tion, the embryos were collected in tubes and frozen at −80 °C until the time of extraction. 
To determine the stage of death, GFP-negative embryos were allowed to age and then 
examined at the microscope. 
2.4. Seizure Phenotypes 
Seizure phenotypes were characterised as previously described [21]. For the me-
chanically-induced seizure assay, 10–15 flies were transferred to an empty vial and left to 
settle for 30 min, then they were vortexed at top power for 10 s. After this we determined 
how many flies have gone into seizure and how long they took to recover. The experi-
ments were performed in triplicate. 
For the temperature induced seizures, the flies were transferred to vials and left to 
settle as above, and then submerged in a water bath at 40 °C for 2 min and recorded with 
a video camera. The video was then analysed to determine how many flies went into 
seizure, and at which time they did so. In this experiment, recovery is almost immediate 
after cooling down, so it is not a relevant parameter. The experiments were also per-
formed with 10–15 flies in triplicate. 
In order to simulate the sudden death, usually associated with status epilepticus (SE), 
we performed longer incubations at 37.5 °C, which is not so effective at causing seizures. 
Vials were submerged in the water bath, incubated for 30 min and then checked that 
some individuals had started to seize. Then, the vials were incubated for a further 15 min, 
and the number of flies that had died was scored. Sample size and replicate number was 
as in the previous experiments. 
The seizure assay in third instar larvae was performed following a published pro-
tocol [19]. In total, 30 larvae per genotype were placed on a Petri dish, and electroshocked 
with a probe composed of two tungsten filaments, 0.1 mm in diameter and 1.2 mm of 
separation between them. The shock was applied in the anterior dorsal part of the larvae, 
just above the central nervous system, by a 3 s pulse at 30 V generated by a Grass S88 
stimulator (Grass instruments; West Warwick, Rhode Island). For each larva, we scored 
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the recovery time, which is defined as the time it takes to resume a normal movement 
pattern after the seizure, usually manifested as paralysis and tonic contractions. 
2.5. Negative Geotaxis 
The climbing experiments were carried out following standard procedures [22]. A 
total of 10–15 flies were transferred to empty vials and left to settle for 30 min. A line was 
drawn with a permanent marker along the circumference of the vial at a distance of 80 
mm from the base. The vials were then hit against a cork pad to knock down the flies to 
the bottom and the flies were video recorded while they attempted to climb back to the 
top. The video was analysed to determine which proportion of flies had managed to cross 
the 80 mm mark after 10 s. The experiments were performed in triplicate, and each rep-
lica was assayed 5 times, allowing half an hour between experiments. 
2.6. Flight Assay 
The method was adapted from Babcock and Ganetzky [23]. 30–40 the flies were in-
troduced in an empty vial and left to settle for 30 min. We built a methacrylate flight 
tester tube, 90 cm high and 12 cm in diameter, with an interior PVC plastic sheet coated 
with rodent trap adhesive glue (Cofan; Ciudad Real, Spain), such as the flies were glued 
to the cylinder wall at variable height dependent on their ability to stabilise their flight. A 
‘drop tube’ was added to ensure that flies entered the flight tester at the same speed, thus 
reducing variability associated with manipulation. The flies were dropped into the tester 
and then the plastic sheet was removed and photographed. The images were analysed 
using the ImageJ 1.53c software (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018). We performed 
three replicates for each experiment, with a total of 80 flies per genotype. 
2.7. Locomotion Assay 
The method was adapted from Stone et al. [24]. Individual flies were placed in a 90 
mm petri dish resting on a white LED light source covered with a paper sheet. The fly 
was recorded by a zenithal video camera for 10 min using the VirtualDub 1.10 software (a 
free and open-source video capture and processing utility written by Avery Lee and li-
censed under the GNU General Public License; https://www.virtualdub.org) at a speed of 
2 photograms per second. The individual photograms were uploaded in ImageJ, and the 
contrast adjusted to facilitate the identification of the object of interest (individual fly) to 
generate a file with the coordinates of the fly in each photogram. Then, the coordinates 
table was introduced in an Excel spreadsheet to calculate the total distance and the av-
erage speed. In addition to this, an internal area, 50 mm in diameter and concentric with 
the larger arena, was defined in order to determine the proportion of time spent in the 
central and peripheral regions of the arena. For each genotype, 10 individual flies were 
assayed in triplicate. 
2.8. Learning and Memory 
These parameters were assessed by the aversive phototaxic suppression assay [22]. 
Flies have positive phototaxis, they tend to move towards a source of light. We con-
structed a T-maze consisting of two transparent plastic vials, one of them darkened with 
aluminium foil, separated by a sliding door. Flies were tested individually, after 16 h 
fasting with only a water-soaked paper to avoid dehydration. Each fly was placed in the 
darkened vial with the door closed, and left to habituate for a few minutes. After this, the 
door was opened and a strong light shined next to the other vial, which also contained a 
filter paper soaked with 120 µL of 0.1 M quinine (Sigma-Aldrich; Saint Louis, MO, USA) 
as an aversive stimulus that should oppose the phototaxic attraction. Each training ses-
sion lasted one minute and was performed six consecutive times. Next, five testing ses-
sion were performed, scoring whether or not the fly crossed the barrier in the 10 s fol-
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lowing the opening of the door. To assess the short term memory, the same flies were 
tested again after five hours. The learning and memory tests were performed in 30 flies of 
each genotype, and in triplicate. 
2.9. Electrophysiology 
Patch clamp recordings from the aCC motoneuron were performed as previously 
described [25]. For both voltage clamp and current clamp experiments, the electrodes 
were made using borosilicate glass capillary tubes (GC100F-10, Harvard Apparatus; 
Edenbridge, UK) pulled with a P-1000 capillary puller (Sutter Instrument; Novato, CA, 
USA) and then fire-polished to a resistance between 10–15 MΩ. 
Signals were recorded using a Multiclamp 700B amplifier linked to a Digidata 1440A 
controlled by pCLAMP (version 10.2, Molecular Devices; Sunnyvale, CA, USA). Re-
cordings were filtered at 10 Hz and sampled at 20 KHz. Recordings of Na+ currents were 
performed using an on-line P4 leak subtraction protocol. Voltage steps were applied 
from a prepulse holding potential of −90 mV. Only cells with an input resistance of >500 
MΩ were accepted for analysis. Cell capacitance was calculated by integrating the area 
under the capacity transients elicited by stepping the cell from −60 to −90 mV for 30 ms. 
2.10. Metabolomics 
Metabolite extraction, spectral recording and data analysis were performed as pre-
viously described [26]. Briefly, for metabolite extraction 20–23 freshly dissected fly heads 
were homogenised and extracted with the chloroform-methanol-water extraction pro-
cedure to separate aqueous and organic extracts, which were lyophilised and kept at −80 
°C. Aqueous extracts were resuspended in 0.1 M phosphate buffer made with deuterated 
water, and organic extracts were resuspended in deuterated chloroform. Then, 
3-(Trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP) and Tetramethylsilane 
(TMS) were used as internal standards for the aqueous and the organic phase, respec-
tively. 1H NMR spectra of the extracts were recorded at 27 °C on a Bruker AVII-600 
spectrometer (Bruker Scientific Instruments; Billerica, MA, USA) using a 5-mm TCI cry-
oprobe, with 512 scans. Water presaturation was applied for aqueous samples to mini-
mise the water signal. In total, six independent replicates containing 20–23 individuals 
each, from two independent experiments were analysed. 
After acquisition, spectra were processed with an exponential line broadening factor 
of 0.5 and automatic phase correction performed. Spectra were then referenced to the 
signal of the internal standards (TSP/TMS) at 0 ppm. The signals were assigned to the 
corresponding metabolites with the help of our previous work [24] and data bases Hu-
man Metabolome Database (HMBD) [27] and BioMagResBank (BMRB) [28]. Spiking ex-
periments with external standards were performed to confirm the assignment of glucose, 
threonine, taurine, and betaine. Spectra were integrated automatically with MestreNova 
12 with the GSD deconvolution option. Integration tables were normalised to total in-
tensity for multivariate data analysis, we used SIMCAP 14.1 (Umetrics, Umeå, Sweden). 
Principal components analysis (PCA) was used as an unsupervised model after univari-
ate scaling of the data. To assess the quality of the each model, the parameters R2 
(goodness of fit) and Q2 (goodness of prediction) were evaluated. A Q2 value ≥ 0.5 was 
considered indicative of a good model. 
2.11. Statistical Analysis 
In all the experiments, sample size and number of replicates were determined with 
the help of the available literature to balance the statistical power required and the ex-
perimental complexity. The sample size of the control and experimental genotypes was 
always identical or highly similar. 
In all the experiments, we applied the Kolmogorov–Smirnov test for normal distri-
bution. In pairwise comparisons between the experimental and control groups, we ap-
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plied the T-test if the distribution was normal, and the non-parametric Mann–Whitney 
test if they were not normal. In the experiments, involving more than two groups or more 
than one variable (variation of the amplitude of sodium currents at different membrane 
potentials, learning and memory), if the distributions were normal we used the one-way 
or two-way ANOVA, followed by Bonferroni post hoc test; if they were not normal we 
used the non-parametric Kruskal–Wallis test. In the lifespan experiments we used the 
Mantel–Cox test. 
The GraphPad Prism software (GraphPad Software, San Diego, CA, USA) was used 
for illustrations and statistics. In scatter plot diagrams, the displayed data are the mean 
and the standard deviation. 
3. Results and Discussion 
3.1. Generation and Validation of the para Knock-Out 
The para gene is one of the largest and most complex in the Drosophila genome, 
spanning nearly 80 kb and with several isoforms generated by alternative splicing and 
start of transcription (Figure 1A). A second gene, Calnexin 14D, is nested within the first 
intron of para. To design the knock-out strategy we downloaded the locus sequence, 
corresponding to bases 16,450,000 to 16,535,000 of the X chromosome reference sequence 
(NC_004354.4). We designed two arms of homology, an A arm of 951 bp ending in the 
base pair just upstream of the start codon, and a B arm of 782 bp, starting 10 bp down-
stream of the start codon (Figure 1B), and both arms were cloned into the pTV[Cherry] 
vector to achieve the gene editing. Due to the design of the strategy, the homologous re-
combination would generate a deletion of 12 bp, including the start codon, followed by 
the insertion of the construct, which would prevent the translation of the full length 
protein. After the generation of the transgenic flies and the induction of the homologous 
recombination, we selected a candidate knock-out insertion. The construct carries the 
mCherry reporter gene with a minimal promoter that normally reproduces the pattern of 
expression of the edited gene; in this case the first indication that our editing had been 
correct was the presence of red fluorescence in the central nervous system (not shown). 
For a thorough validation of the insertion, we performed two PCRs at either end of the 
insertion, with one primer designed from the transgene sequence and a second primer 
that would hybridise in the flanking genomic sequence, beyond the sequence used to 
generate each one of the arms of homology, to discard non-specific insertions. Both PCRs 
were successful, and the products were sequenced to check that the sequence was the 
expected from a legitimate recombination. 
After this, we removed most of the cassette by crossing to flies carrying it to flies 
expressing the Cre recombinase, leaving just a minimal attP insertion and the 12-bp de-
letion. The excision was also validated by PCR with primers designed from the genomic 
region flanking the insertion and sequencing. For all the subsequent experiments, we 
compared the paraKO flies to a control genotype. Since the new allele was generated in a 
w1118 background, and this can affect viability and fitness, the experimental genotype was 
an outcross of the paraKO stock to wild type Canton-S, from which the paraKO/para+ females 
were selected. For the control, we used a stock generated from the siblings of fly used to 
make the paraKO stock. These flies had gone through the same genetic crosses, but the 
gene editing construct had failed to recombine. These flies were also crossed to Canton-S 
to obtain the control individuals. 
 




Figure 1. Generation and validation of the para knock-out. (A) Structure of the para locus, filled arrows represent tran-
scribed regions, the coding and non-coding regions are shaded black and grey respectively; the flags indicate the three 
alternative start of transcription sites; the red arrow represents the Calnexin 14D gene nested within a para intron. (B) 
Magnification of the boxed area around the start of transcription: the green boxes indicate the extension of the A and B 
arms of homology flanking the start codon; the sequence amplified in the qPCR to estimate para mRNA levels is indicated 
in blue. (C,D) relative para mRNA levels in control versus paraKO/para+ heterozygote females (C) and in control versus 
paraKO hemizygote/homozygote embryos (D) estimated by quantitative PCR. (E) Genetics of the para locus regarding 
embryonic lethality and convulsive phenotype. (F,F’) proportion of flies undergoing seizures at 40 °C displayed as total 
number of flies at the end of the experiment (F) and as temporal dynamics of the seizures (F’). (G) Estimation of deaths in 
status epilepticus by exposure to a moderate heat shock at 37.5 °C for 15 min. (C,D,G) Student’s t-test; (F) Mann-Whitney. 
Bars represent mean ± SD (** p < 0.01; *** p < 0.005; **** p < 0.0001). 
Both the original and the minimal insertions were homozygous lethal in females and 
hemizygous lethal in males, so we kept the mutation over an FM7c X-chromosome bal-
ancer. All the males in the stock were FM7c/Y, and the females were paraKO/FM7c. In or-
der to determine the period of lethality, we put the paraKO allele over an FM7c-GFP bal-
ancer, which expresses GFP under the pattern of the Kruppel gene. GFP-negative embryos 
were able to complete development, displayed normal cuticular structures, but were 
unable to hatch. Therefore, lethality was most probably due to impairment of the neural 
function. 
Gene editing and deletion of the first four codons should prevent protein transla-
tion, but since the next in-frame start codon is the fourth exon several kilobases down-
stream, it was possible that the mutant transcript was unstable due to nonsense-mediated 
mRNA decay. To test this possibility we designed a quantitative PCR primer pair which 
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should amplify from the end of the first coding exon up to the third exon, both in regions 
downstream of the edited sequence. We performed the quantitative PCR in heterozygous 
adult female head extracts, and we observed a marked reduction in the para transcript 
levels (Figure 1C). In addition, we also quantitated transcription in homozy-
gous/hemizygous embryos selected by the absence of GFP fluorescence, in this case the 
mRNA was virtually absent (Figure 1D). Expression of the control gene rp49 was un-
changed. These results confirm that the editing of the para gene destabilises the transcript 
and results in a full loss of function of the locus. 
Regarding the genetics of the allele, in addition to recessive embryonic lethal, it is 
dominant regarding seizure susceptibility, as expected (Figure 1E). The heterozygous 
females displayed a convulsive phenotype upon heat shock, but not by mechanical stress 
caused by vortexing (see below). Since the mutation abolishes gene expression, the most 
likely explanation is that it is haploinsufficient. Another allele, parabss1, has been described 
as dominant but in this case as the result of a gain of function [29]. In agreement with this, 
the parabss1/paraKO heterozygote was not convulsive due to the compensation of loss and 
gain of function effects. 
Temperature-induced seizures are the first manifestation of DS, and these are fol-
lowed by further febrile or afebrile seizures, which are the most disabling and 
life-threatening features in DS patients [1]. This phenotype is also present in preclinical 
models of DS [30]. Consistent with this, the most evident convulsive phenotype of paraKO 
flies was obtained by heat shock, submerging the vial in a 40 °C water bath (Figure 1F). In 
these conditions, there was no effect on control females flies, but around 80% of hetero-
zygote females suffered seizures; most of the time they laid on their back, paralyzed, and 
suffered occasional spasms. When we looked at the temporal pattern, the first flies 
started to seize as early as 20 s after being submerged, and in one minute they ap-
proached the maximum level of 80% (Figure 1F’). The paralyzed flies resumed their 
normal behaviour immediately after removing the vials from the water bath, which was 
already described in other Drosophila models of DS [18]. 
Another problem associated with the disease is a considerably high mortality rate, 
mostly caused by SUDEP or by SE [31]. Regarding SUDEP, control and paraKO flies did 
not show any difference in survival, therefore there was no SUDEP-like phenotype in our 
model. In contrast, most of the mouse models of DS have a high mortality rate [6,32–37]. 
This is probably due to the fact that paraKO flies did not have spontaneous seizure activity 
when reared in normal conditions, unlike the different mouse models. In order to gener-
ate a condition similar to the SE, an experiment was designed in which the flies subject to 
a longer stimulus, by keeping them 45 min in a hot water bath at 37.5 °C, and then scored 
the number of flies that had not survived this condition. There was a statistically signifi-
cant increase of around three-fold in death in the paraKO flies (Figure 1G). Therefore, a 
maintained seizure state similar to SE did affect the paraKO heterozygote females differ-
entially, regarding lethality. 
3.2. The paraKO Flies Suffer Additional Neuromuscular and Cognitive Alterations 
Although seizures are the most disabling and life-threatening feature in DS patients, 
they suffer from additional impairments, such as movement disorders, learning diffi-
culty, and cognitive and behavioural impairment [1,38–40]. These alterations are also 
present in available zebrafish and mouse models [30,41]. In order to evaluate the neu-
romuscular fitness of the paraKO flies, we performed tests for negative geotaxis and flight. 
In the negative geotaxis test, flies are knocked down to the bottom of the vial, and then 
scored for their ability to climb back to the top. In this test the performance of the paraKO 
flies was slightly worse than for the control flies (Figure 2A). The flight test measures the 
ability of individual flies to stabilise their flight and reach the wall after being dropped 
into a cylinder. In this case, the paraKO flies also took longer to stabilise than control flies 
(Figure 2B). Looking at the performance in more detail, control flies tended reach the wall 
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15 to 30 cm from the drop point, while most paraKO flies stabilised at 30–35 cm (Figure 
2B’). Overall, the paraKO flies had worsened performance in climbing and flight tests. 
 
Figure 2. Neuromuscular and behavioural analyses. (A) Negative geotaxis assay, proportion of the flies that reached the 8 
cm mark in 10 s. (B,B’) Flight test, indicating the average distance of stabilisation of the control and paraKO flies (B), as well 
as the distribution of the distances reached in each genotype (B’). (C–C’’’) For the locomotion assay, individual flies were 
filmed for 10 min in a closed arena 90 mm in diameter, and the resulting video was analysed to extract the relevant pa-
rameters (C); these included total distance walked (C’), average speed (C’’) and time spent in an internal area of 50 mm. 
(D,D’) For the learning and memory assays, individual flies were subject to an aversive phototaxic suppression assay (D) 
at two different times, immediately after training (P0) and after 5 h (P5) to evaluate each one of these parameters (D’). 
(A,B) Mann-Whitney test; (C–C’’) Student’s t-test < (D’) one-way ANOVA plus Kruskal–Wallis. Bars represent mean ± SD 
(* p < 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.0001). 
Another test that can be used to analyse more complex behaviours is a locomotion 
assay in a closed arena. The intensity and patterns of locomotion are related to motility 
and to the degree of anxiety of the fly (Mohammad et al., 2016), similar to mice and other 
animals: flies in an enclosed space tend to remain close to the walls for safety. In this case, 
individual flies were allowed to explore a circular arena 90 mm in diameter, and were 
filmed during 10 min; and then image analysis software was used to extract motility pa-
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rameters (Figure 2C). Compared to the control flies, the paraKO flies walked a shorter 
distance and did so at a lower average speed (Figure 2C,C’). This was a quantitative dif-
ference that could be equivalent to the performance in the negative geotaxis and flight 
tests, just reflecting a worse neuromuscular performance. A third analysis, the time spent 
in the centre of the arena, reflects a more complex behaviour, the pattern of movement; 
which can depend on decision such as the choice between exploratory or protective 
paths. In this case, the paraKO flies spent more time in an internal area, 50 mm in diameter. 
Anxiety is one of the comorbidities in DS patients [42], and similar anxiety phenotypes 
have been described in open field experiments with mouse models [37]. 
Drosophila has positive phototaxis, and this behaviour can be used to test learning 
and short term memory by exposure to a negative stimulus (Figure 1D). To this end, in-
dividual flies were left to habituate to the system inside a darkened chamber, which was 
then connected to an illuminated chamber to attract them. Following their phototaxic 
impulse they tended to move into the illuminated chamber, but there they found a filter 
paper soaked in quinine, which has a bitter taste and acts as a repellent. After this train-
ing, the flies were scored to avoid the illuminated chamber; as the experiments were 
performed straight away, we could consider this as a measure of their learning ability. 
The experiments were repeated after five minutes, and in this case it would be an as-
sessment of short-term memory. Although around 40% of control flies learned to avoid 
the light, only half this proportion of the paraKO flies did the same (Figure 2D’), and the 
difference was statistically significant (*** p < 0.001). In the second experiment, fewer flies 
remembered to avoid the quinine, and the paraKO flies also performed worse than the 
control (* p < 0.05). The reduction in number of flies remembering if avoid the light was 
similar within both genotypes, but this reduction was not statistically significant. There-
fore, we can conclude that paraKO flies have an impairment in their learning ability, but it 
is not that clear that they have a worse short-term memory. 
3.3. The paraKO Larvae Have Electrophysiological Defects 
Our previous results showed that the para knock out suffered temperature-induced 
seizures, most probably due to the alteration of sodium currents. In order to characterise 
these currents we decided to carry out patch clamp electrophysiological analyses of the 
mutant neurons. We performed these studies using the well characterised aCC motor 
neurons in late third instar larvae (120 h after egg laying), just before puparium for-
mation. These neurons are easy to manipulate and identifiable with the use of fluorescent 
genetically-engineered probes (Baines et al., 2017). In order to find out if larvae also had a 
convulsive genotype, we used a well-established assay, electroshock-induced seizures. 
When the electroshock is applied with a metal probe, the larvae suffer spasms and tonic 
contractions for a period of time, and finally recover and resume their normal ambulation 
pattern. The paraKO larvae had a significantly longer recovery time (Figure 3A), demon-
strating that the seizure susceptibility is already established at this developmental stage. 




Figure 3. Electrophysiological analyses. (A). Recovery time of third instar larvae after electroshock. (B). Capacitance of 
the aCC neurons in which the sodium currents were measured. (C–C’’). Analysis of sodium currents in voltage clamp 
experiments at a fixed membrane potential: amplitude of transient sodium currents (C), persistent sodium currents (C’), 
and the ratio of the amplitudes of transient to persistent sodium currents (C’’). (D,D’) Variation of the amplitude of tran-
sient (D) and persistent (D’) sodium currents at different membrane potentials. (A–C), Student’s t-test; (C’,C’’) 
Mann–Whitney; (D,D’), two-way ANOVA followed by Bonferroni’s multiple comparisons test. Bars represent mean ± SD 
(* p < 0.05; ** p < 0.01). 
In order to identify possible defects in sodium currents, we performed voltage 
clamp, to analyse the sodium transient and persistent currents (NaT and NaP, respec-
tively). As their name indicates, NaT is a brief, but large, current that supports the up-
stroke of action potentials. This current component is transient due to internal block of 
the ion pore. By contrast, NaP, which represent random reopenings of inactivated chan-
nels, is smaller in amplitude but longer in duration. A first observation was that in the 
dissected larval brains the aCC neurons seemed to be smaller. One of the parameters 
obtained from the patch clamp assays is the capacitance of the clamped cell, and this is 
directly proportional to the cell size. aCC neurons in the paraKO brains had a lower ca-
pacitance than wild type neurons (Figure 3B), so we can conclude that the mutant neu-
rons are indeed smaller. 
Regarding the amplitude of the sodium currents, NaT did not show any significant 
changes (Figure 3C), while paraKO cells had an increased NaP (Figure 3C’); and conse-
quently also an increased NaP/NaT ratio (Figure 3C’’). An increase in this ratio is a defin-
ing feature of Drosophila seizure mutants, and is corrected in anticonvulsant treatments 
[19,25,43]. 
In addition to their amplitude at a fixed membrane potential, we analysed the cur-
rent: voltage relationship for each current component, to shed light on the kinetics of the 
sodium channels. Regarding the initial NaT, in both genotypes Na entry started at a sim-
ilar membrane potential, but they reached their maximum intensity at different poten-
tials, −20 mV for wild type neurons and at −10 mV for paraKO neurons (Figure 3D). 
Therefore, in the mutant genotype the channel activation was delayed compared to the 
wild type. The trend of the NaP was the opposite (Figure 3D’): paraKO neurons started with 
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increased Nap currents from higher membrane potentials, and this difference was most 
significant at potentials of −40 and −30 mV, when the mutant neurons reached their peak. 
In contrast, in wild type neurons the highest current was reached at −20 mV. In summary, 
in paraKO neurons NaP started at higher membrane potential and had an increased am-
plitude. This would mean that this current component is more easily activated in paraKO 
neurons than in wild type. 
The elevated NaP persistent sodium currents, are a common feature in epilepsy, in-
cluding SCN1A-related syndromes, and therefore targeting them is an interesting thera-
peutic strategy [44,45]. 
3.4. The Metabolome of paraKO Fly Heads 
During the experiments to evaluate the learning and memory of the paraKO flies we 
realised that they had an increased mortality rate during the previous fasting period, 
which pointed towards a metabolic alteration. This result was somewhat surprising, 
since in normal conditions both genotypes have no differences regarding viability or 
spontaneous seizures. However, in this case the flies are subjected to a severe 16-h star-
vation to make them more active in the search for food. It is only in these strenuous situ-
ation that the underlying metabolic alterations are evident. 
Recent work Drosophila para mutants aimed at understanding dietary interventions, 
such as the ketogenic diet have revealed that certain food compositions can alleviate the 
symptoms [46,47]. This evidence led us to carry out a metabolomic analysis to determine 
if there were differences in basal metabolite levels between the paraKO and the control 
flies. Since our focus was in neuronal phenotypes, we performed this analysis in adult 
head extracts, in which the neural tissue is over-represented in comparison with other 
anatomical regions. 
From each head homogenate, we separated the aqueous and organic phases, to ob-
tain information about the metabolome and the lipidome. 1H NMR spectra were acquired 
for each phase, and the main signals identified and quantified. Visual inspection indi-
cated some anormal, large signals in samples DH2 and DH4, probably coming from 
contaminations during the extraction process. For this reason we decided to exclude this 
samples from the analysis, which would still leave five samples per genotype, so we did 
not consider it necessary to include new replicates. 
Principal component analyses indicated that there was a separation of the genotypes 
in both types of extracts (Figure 4A,B), indicating differences in the metabolic profile. 
Next, by performing a univariate statistical analysis, we identified those metabolites that 
had the most significant differences. In the aqueous extracts (Figure 4C), we found in-
creased levels for several amino acids: valine, isoleucine, threonine, arginine, proline, and 
β-alanine. In addition, there were increased levels of lactate and succinate, which was 
indicative of a mitochondrial dysfunction and an increase in oxidative stress. 




Figure 4. Metabolomic analysis. (A) PCA score plot of 1H NMR spectra of aqueous head extracts, samples DH2 and DH4 
were excluded. UV scaling. R2X(cum) = 0.74, Q2(cum) = 0.31. 3 component model. (B). PCA score plot of 1H NMR spectra 
of organic head extracts o. UV scaling. R2X(cum) = 0.73, Q2(cum) = 0.28. 2 component model. (C) Relative abundance of 
metabolites in the aqueous extracts that showed significant differences. (D) Relative abundance of metabolites in the or-
ganic extracts that showed significant differences. In (C,D), relative abundance is calculated as concentration normalised 
to the total area of the spectrum. In all the experiments Student’s t-test was used (* p < 0.05, ** p < 0.01). 
Although amino acid imbalance has been reported in epileptic patients, the patterns 
of abundance are not consistent and may vary depending on the particular form of the 
disease [48]. In contrast, metabolic imbalance and increased oxidative stress are common 
hallmarks in different types of epilepsy [8,49]. The ketogenic diet, an intervention that is 
being used in DS, can impact of both the amino acid imbalance and the neuroinflamma-
tion caused by oxidative stress [50,51]. Some of these alterations have been already de-
scribed in DS models and patients, such as the increase in lactate in the serum of patients, 
or the increase in succinate in zebrafish models [10,52]. Oxidative stress is linked to in-
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creased neuroinflammation in epilepsy [9,53], and this has also been found in DS models 
and patients [40,54]. 
The aqueous extracts of the paraKO heads also had increased levels of the GABA 
neurotransmitter. Since DS affects primarily gabaergic neurons, it is tempting to specu-
late that this represents an accumulation of neurotransmitter due to the lack of activity of 
the neuron, but this possibility would require further investigation. 
Regarding the organic extracts, there were differences in some lipids, such as de-
creased levels of phospholipids and fatty esters, or slightly increased levels of lipid chain 
and triglycerides (Figure 4D). The increase in triglycerides, in combination with a reduc-
tion in phospholipids and linear fatty esters (membrane components), is an indicator for 
the accumulation of lipids in the form of lipid droplet inside the cells. This is further 
confirmed by the reduction in the aqueous metabolite glycerol, which is required for tri-
glyceride synthesis. Lipid droplets are cellular fuel stores, signalling hubs, protective 
waste reservoirs for hyperactive neurons, products of lysosomal dysregulation, and 
hallmarks of ageing [55]. Within the nervous system, lipid droplets are associated with 
several pathologies including amyotrophic lateral sclerosis, and Alzheimer’s, Hunting-
ton’s and Parkinson’s disease, and can be correlated with increased oxidative stress and 
inflammation [56–58]. Therefore, the lipidomics of the head extracts would also be con-
sistent with neuroinflammation in the paraKO flies. 
4. Conclusions 
In this work, we describe the generation and characterisation of a knock-out allele in 
the para gene of Drosophila, as a tool for research and therapeutic development in DS. In 
the new mutant, gene expression was completely abolished, so it is a null allele. Re-
garding viability, the new allele is a recessive lethal, and the period of lethality has been 
established as the end of embryonic development, without any evident anatomical de-
fects. Genetically, it is a haplo-insufficient dominant allele regarding seizures and other 
neurological phenotypes. 
The additional neuromuscular, behavioural, and learning defects are highly remi-
niscent of those present in DS patients. The heterozygote paraKO flies also display elec-
trophysiological alterations similar to those present in DS and other forms of epilepsies 
and sodium channelopathies, mainly an increase in persistent sodium currents, and a 
defective nerve conduction. The heterozygote paraKO flies have a metabolomic profile 
consistent with metabolic imbalance, mitochondrial dysfunction, increased oxidative 
stress, and neuroinflammation. 
In summary, the genetics, neurobiology, and physiology of this new model is rep-
resentative of many of the traits present in DS patients. Therefore, it may constitute a 
useful tool to investigate the pathophysiology of the disease and to search for new 
treatments, biomarkers or genetic modifiers. 
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Appendix A 
Table A1. Primers. Restriction enzyme target sequences are underlined 
Use Primer Sequence Direction 
Generation of the A 
arm of homology 
AGAGGCTAGCCAGTATTCGGGCAACTGCTG Forward 
AGAGAGGTACCTGTCTATGCGGCCAACGATGA Reverse 
Generation of the B 
arm of homology 
AGAGAACTAGTTCCGACTCGATATCTGAGGAAG Forward 
GTGGACATATGCTGTTCTAGT Reverse 











rp49 qPCR (control) 
CGTTTACTGCGGCGAGAT Forward 
GCGCTCGACAATCTCCTT Reverse 
Validation of the exci-
sion by PCR 
CGAAGATGAGGAAGACACAT Forward 
GACAGAATAGACAGTATGCAG Reverse 
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70I-SceI}4A/TM3, P{w+mC = hs-hid}14, Sb1 
B#25679 
paraKO/FM7c-GFP This work 
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